原文：
Barely four months after being named to the board of CardiAQ Valve Technologies, Robrecht "Rob" Michiels led a group of angel investors in a $6.5 million boon for the Winchester, Mass.-based start-up. Michiels, the former COO of CoreValve Inc. before that Irvine, Calif.-based firm's $700 million buyout by medical device colossus Medtronic Inc. (NYSE: MDT) in February, 2009. He joined the CardiAQ board in late September. Michiels led the fundraising round with the same group of angel investors who invested in CoreValve back in 2002. Broadview Ventures also invested in the round. The funding, which includes the conversion of all previous debt, will be used to validate CardiAQ's technology and carry it through to initial "first-in-man" studies, according to a press release. CardiAQ is developing a transcatheter mitral valve implant, designed to enable physicians to implant a new mitral valve within a beating heart, avoiding open-heart surgery.
原文来自：http://www.massdevice.com/news/cardiaq-valve-drums-65-million-series-round

CardiAQ Valve drums up $6.5 million in Series A round;是由提供的阀门新闻，中文译文仅供参考(上海日美阀门制造有限公司还生产 及角式柱塞阀、柱塞型闸阀，四通四密封球阀，手动刀形闸阀，丝口柱塞阀，欢迎您的选购。)
以下是参考译文：

译文：CardiAQ阀门技术
仅仅四年后任命为CardiAQ阀门技术，罗布雷赫特“罗布”米希尔斯董事会在1个月，率领的温彻斯特，麻省启动，六百五点零零零万美元实惠的天使投资者。 米希尔斯，公司的CoreValve之前，位于加州Irvine前首席运营官的公司7亿美元的医疗设备巨头美敦力公司（NYSE：MDT）的收购于2009年2月。他于9月下旬CardiAQ板。米希尔斯领导同谁投资CoreValve 2002年回天使投资同一组募款。百威风险投资公司也投资轮。 这些资金，其中包括所有以前的债务转换，将用于验证CardiAQ的技术和贯彻始终，初步“首次在人”的研究，据一份新闻稿。 CardiAQ正在开发一种植入导管二尖瓣，目的是使医生在植入新的心脏跳动二尖瓣，避免心内直视手术。

更多新闻